FDAFDA · Food and drugs·Recall number D-0248-2019
ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA. NDC: 66733-958-23
Published November 21, 2018 · Recall initiated: November 8, 2018
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Labeling: Missing label; potential for missing primary container label on the vial.
What to do
Voluntary: Firm initiated · Letter
Recall details
- Brand
- ERBITUX
- Manufacturer
- Eli Lilly & Co
- Distributor
- AL, AZ, CA, KS, LA, MS, OH, OR, TN, TX and Puerto Rico
- Lot
- Lot number: C1700167, exp 9/2020
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Sell products like this?
Recalert watches your whole catalog for recalls like this one, automatically.